Physician profile
Charles Mcwilliams
NPI 1295221166
$2,268.19
in general payments reported to CMS, 2019-2025
19 companies · $654 in 2025
The $654 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $462 · 2023: $442 · 2024: $480 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $630.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $453.19 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $264.06 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $176.95 | 2022-2025 | Freestyle Libre, Jot Dx |
| Glaxosmithkline, LLC. | $164.17 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $152.44 | 2021-2025 | |
| Exact Sciences Corporation | $61.18 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $48.12 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $47.30 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $42.12 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $39.15 | 2022 | |
| Dexcom, INC. | $35.62 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.76 | 2021-2023 | Xifaxan |
| Amgen INC. | $31.95 | 2025 | Repatha |
| Amarin Pharma, INC. | $21.79 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $18.12 | 2024 | Contrave |
| Corcept Therapeutics | $17.29 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.49 | 2024 | Jardiance |
| Boston Scientific Corporation | $13.96 | 2024 | Varithena Administration Pack |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mcwilliams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.